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To add new insight to our previous work on the molecular epidemiology of Bordetella pertussis in Argentina, 
the prn and ptxSl gene sequences and pulsed-fleld gel electrophoresis (PFGE) profiles of 57 clinical isolates 
obtained during two periods, 1969 to 1989 and 1997 to 2006, were analyzed. Non-vaccine-type ptxSIA was 
detected in isolates obtained since 1969. From 1989 on, a shift of predominance from the vaccine prnl type to 
the nonvaccine pm2 type was observed. This was also reflected in a transition of PFGE group IV to group VI. 
These results show that nonvaccine B. pertussis strains are currently circulating. To analyze whether the 
observed genomic divergences between vaccine strains and clinical isolates have functional implications, 
protection assays using the intranasal mouse challenge model were performed. For such experiments, the 
clinical isolate B. pertussis 106 was selected as representative of circulating bacteria, since it came from the 
major group of the PFGE dendrogram (PFGE group VI). Groups of mice were immunized either with 
diphtheria-tetanus-whole-cell pertussis vaccine (ptxSIB prnl) or a vaccine prepared by us containing B. 
pertussis 106. Immunized mice were then challenged with a B. pertussis vaccine strain (Tohama, harboring 
ptxSIB and prnl) or the clinical isolate B. pertussis 106 (ptxSIA prn2). An adequate bacterial-elimination rate 
was observed only when mice were immunized and challenged with the same kind of strain. For further 
characterization, comparative proteomic profiling of enriched membrane proteins was done using three 
vaccine strains and the selected B. pertussis 106 clinical isolate. By matrix-assisted laser desorption ionization­
time of flight mass spectrometry analysis, a total of 54 proteins were identified. This methodology allowed us 
to detect differing proteins among the four strains studied and, in particular, to distinguish the three vaccine 
strains from each other, as well as the vaccine strains from the clinical isolate. The differing proteins observed 
have cellular roles associated with amino acid and carbohydrate transport and metabolism. Some of them have 
been proposed as novel vaccine candidate proteins for other pathogens. Overall, the global strategy described 
here is presented as a good tool for the development of next-generation acellular vaccines.
Pertussis is an infectious respiratory disease caused by the 
bacterium Bordetella pertussis, an exclusively human pathogen. 
This disease, though preventable by vaccination, remains one 
of the top 10 causes of death worldwide in childhood. More­
over, in countries with highly vaccinated populations, a pertus­
sis resurgence has been reported (2, 13, 14, 19, 36, 40, 43, 50). 
Several explanations have been suggested for this resurgence 
in such populations: low efficacy of the vaccine used, waning 
immunity in the absence of both natural and vaccinal boosters 
after 18 months of age, and adaptation of the circulating B. 
pertussis population (24, 27,31,39, 41, 46, 51). One explanation 
is based on studies of B. pertussis strains, first from The Neth­
erlands and then from other countries, that focused on
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genomic analysis by pulsed-field gel electrophoresis (PFGE) 
and on sequences of the genes that code for two immunogens, 
pertactin (pm) and the SI subunit of pertussis toxin (ptxSl) (8, 
19, 21, 26, 37, 40, 41). Data from these studies have been 
interpreted to suggest that vaccination selects for strains that 
have different genotypes from those used to make the vaccine, 
allowing the spread of escape mutants (15, 34, 40). This vac- 
cine-driven antigenic evasion seems not to be exclusive to per­
tussis, since a growing body of evidence indicates it exists for at 
least three other diseases: hepatitis B virus, Streptococcus pneu­
moniae, and Haemophilus influenzae infections (5, 7,10,11, 44, 
47, 48).
In Argentina during previous years, an increase in the per­
tussis incidence was registered by the Public Health Ministry, 
even before improvements in diagnostic methodology were 
introduced. In that country, whole-cell pertussis vaccine was 
introduced in the 1960s, and it is still the only kind of pertussis 
vaccine being used. Since 1985, the vaccination schedule has 
been 2, 4, 6, and 18 months of age, with a school entry booster 
at 5 to 6 years of age. Molecular characterization of B. pertussis
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isolates (n = 28) obtained in Argentina from 1997 to 2003 was 
done (19). The isolates appeared to be genotypically different 
from the vaccine strain in use. The isolates were comprised of 
pttSlA (100%) andpm2 (93%) orprnl orpm7 (7%) variants. 
These allelic variants are different from those present in the 
vaccine strain (ptxSIB or ptxSID and prnl) but identical to 
those found in European and North American countries.
Though more epidemiological and molecular data should be 
collected in order to describe more precisely the pertussis 
disease scenario, it is clear that the control of pertussis requires 
improvement. Currently used pertussis vaccines in many coun­
tries are based on strains, or proteins obtained from strains, 
isolated before 1957, which are different from the currently 
circulating bacteria.
Thus, novel proteins from contemporary isolates should be 
considered in the design of new acellular vaccines. Surface 
proteins play a fundamental role in the interaction between the 
bacterial cell and its environment; hence, these bacterial con­
stituents may become components of such vaccines. Compar­
ison of multiple exposed proteins in B. pertussis strains used at 
present in vaccine production with contemporary circulating 
strains may allow the identification of new immunogens that 
can be incorporated in a new, broadly protective vaccine.
In this study, a procedure that allows the identification of 
surface-accessible proteins in B. pertussis is described for the 
first time. This methodology was applied to compare enriched 
membrane samples obtained from well-known laboratory- 
adapted B. pertussis strains widely used for vaccine production 
and a B. pertussis local isolate. The results obtained revealed 
that genomic divergence that seems to have a role in pertussis 
protection, as demonstrated here using the accepted animal 
model, could be extended to the bacterial surface proteome. 
Thus, this new insight into proteins located on the surfaces of 
B. pertussis strains may assist in the identification of potential 
vaccine candidates. Overall, this report presents an attractive 
approach for comparison of the surfaces of Bordetella strains 
and provides a framework for future proteomic analyses.
MATERIALS AND METHODS
Clinical isolates. In this study, we characterized 57 B. pertussis isolates, mostly 
collected from patients residing in Buenos Aires (Argentina) from 1997 to 2006. 
Isolates from 1969, 1971, 1982, and 1989 were also included. Nasopharyngeal 
aspirate and Dacron swab samples were obtained from patients with a clinical 
diagnosis of pertussis, and Bordet-Gengou agar (BGA) supplemented with de- 
fibrinated sheep blood was used for primary culture. Inoculated plates incubated 
at 36°C were monitored daily for 10 days. Suspected colonies were Gram stained 
and tested by agglutination test with antiserum for B. pertussis (Murex Diagnos­
tic, Dartfort, England) and specific B. pertussis PGR (22, 32). Biochemical typing 
using the API 20 NE system (bioMerieux, Marcy l’Etoile, France) was also 
performed on the clinical isolates. The ages of patients ranged from 1 month to 
5 years, with the median age being 4 months. Thirty-three patients from whom 
bacteria were isolated were less than 18 months old, and only one was 5 years old. 
For the other positive culture patients, no data on age were reported.
PCR, sequencing, and PFGE. PGR, sequencing, and PFGE were performed 
according to standardized recommendations for B. pertussis typing (38). Bacteria 
were cultivated on BGA containing defibrinated sheep blood at 36°C for 72 h. 
For PFGE, B. pertussis strains 134 (United States), 509 (The Netherlands and 
Mexico), 10536, Tohama (Japan), and 18323 (United States) were used as ref­
erence strains.
Briefly, DNA sequencing of relevant regions of the pm and ptxSl genes was 
performed on PCR fragments as described by Mooi et al. (38). For sequencing 
of region 1, the primer pair AF/AR (5'-CAATGTCACGGTCCAA-375'-GCA 
AGGTGATCGACAGGG-3') was used, and for sequencing of region 2, the 
primer pair BF/BR (5'-AGCTGGGCGGTTCAAGGT-375'-CCGGATTCAGG 
CGCAACTC-3') was used. For pertussis toxin, primers S1-F2 (5'-CCCCTGCC 
ATGGTGTGATC-3') and S1-R2 (5'-AGAGCGTCTTGCGGTCGATC-3') 
were used to amplify a 930-bp product that contained the completeptxSl gene. 
S1-F2/S1-R2 were also used for sequencing (18). Mutations were confirmed by 
sequencing using two additional primers, S1-MF/S1-MR (5'-ACAATGCCGGC 
CGTATCCTC-375'-TTCGAAGTACGAGCTGGCGG-3').
All clinical isolates and reference strains were genotyped by PFGE using the 
restriction enzyme Xbal (Promega) with a CHEF-DR III apparatus (Bio-Rad 
Laboratories) at 6 V/cm with a 120 angle and pulses of 5 to 6 s for 19 h at 14°C.
Gels were stained for 40 min in 500 ml deionized water containing 50 pl of a 
10-mg/ml solution of ethidium bromide. Unbound ethidium bromide was re­
moved by washing the gels in deionized water for 60 min. DNA fragments were 
visualized on a UV transilluminator, and the gels were photographed with a Gel 
Doc 2000 system.
The Tohama strain was used in each gel as an external quality control to assess 
whether the reproducibility of its banding pattern was consistent with those 
previously published and between runs.
BioNumerics (Applied Maths, Sint-Martens-Latem, Belgium) version 3.5 soft­
ware was used to normalize the DNA fragment migration distances relative to 
those of Salmonella enterica serotype Braenderup strain H9812. DNA fragments 
were analyzed, with at least one band discrepancy? as the basis for discriminating 
among profiles.
The unweighted pair group method using arithmetic averages was used as the 
clustering method, with a 1% band tolerance and 1% optimization settings with 
the Dice coefficient. All profiles were verified by visual comparison.
Murine respiratory-infection model. Female BALB/c mice at 3 to 4 weeks of 
age from Biol SAIC, Argentina, were used as a model of in vivo respiratory 
infection by B. pertussis. Bacteria grown on BGA were resuspended and adjusted 
to approximately 108 CFU ml-1 in phosphate-buffered saline (PBS). Fifty mi­
croliters of a bacterial suspension of each strain studied was delivered intrana- 
sally to each mouse via an air displacement pipette. At different times postin­
oculation, three mice from each group were sacrificed, and the lungs were 
removed aseptically. The lungs were homogenized in PBS, and appropriate 
dilutions were plated onto BGA to determine the number of viable bacteria 
present in the lungs. All the experiments were performed two times, and they 
gave consistent results.
Active immunization and intranasal challenge. Female BALB/c mice were 
obtained at 4 weeks of age from Biol SAIC, Argentina. The animal protocol was 
performed according to the study by Guiso et al. (23). Groups of BALB/c mice 
were immunized intraperitoneally with 1/10 of the human dose of diphtheria- 
tetanus-whole-cell pertussis vaccine (ptxSIB prnl), following a two-dose sched­
ule over a period of 2 weeks. The mice were challenged 2 weeks after the second 
immunization by nasal challenge with a B. pertussis vaccine strain (Tohama, 
harboringptxSIB and prnl) or the clinical isolate B. pertussis 106 (ptxSlA prnl) 
delivered from a culture containing 108 bacteria per ml. We also evaluated the 
potential for bacterial clearance of a vaccine prepared by us containing a B. 
pertussis 106 clinical isolate (wPSpl06).
The lungs of infected animals were aseptically removed, homogenized in 
sterile PBS, serially diluted, and then plated on BGA plates to determine bac­
terial recovery at different time points during the course of infection. The out­
come of the challenge was followed by performing CFU counts on lung homog­
enates from individual mice.
All the experiments were performed three times, and they gave consistent 
results.
Statistical analysis. Means and standard deviations were calculated from 
logio-transformed CFU numbers. Differences among means were assessed by 
two-tailed Student’s t tests, with significance accepted as a P value of <0.05.
Membrane protein enrichment. The membrane fraction of B. pertussis was 
prepared as described previously (6) with minor modifications. B. pertussis cells 
were harvested by centrifugation (10,000 X g; 30 min; 4°C) and washed twice with 
low-salt washing buffer containing 3 mM KQ, 68 mM NaQ, 1.5 mM KH2PO4, 
and 9 mM NaH2PO4. The cells were suspended in 10 mM Tris-HCl (pH 8.5) 
supplemented with phenylmethylsulfonyl fluoride and protease inhibitor cocktail 
tablets (Roche Applied Science) and then disrupted with an ultrasonicator 
(Sonics & Materials, Inc., Danbury, CT). DNase and RNase (20 pg/ml each) 
were added to the cell suspension, and the mixture was incubated at 37°C for 1 h. 
The unbroken cells were removed by centrifugation (12,000 : : g; 30 min; 4°C), 
and the supernatant was retained. Total membrane proteins were then collected 
by centrifugation (30,000 :: g; 1 h; 4°C) and resuspended in 7 M urea, 2 M 
thiourea, 10% isopropanol, and 2% Triton X-100. Membrane proteins were 
divided into aliquots and stored at —20°C until they were used.
For each strain, sample preparation, two-dimensional electrophoresis (2-DE), 
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and protein identification were repeated at least four times to establish repro­
ducibility.
Protein quantification. Protein concentrations were determined by the Brad­
ford method (4), with bovine serum albumin as a standard.
2-DE. Isoelectric focusing (IEF) was performed by using immobilized pH 
gradient strips (Immobiline DryStrip; Amersham Biosciences). Portions (200 |xg) 
of the membrane proteins were applied to 7-cm strips in a pH range from 4.0 to 
7.0. The immobilized pH gradient strips were rehydrated overnight at room 
temperature with 125 pl of rehydration buffer (7 M urea, 2 M thiourea, 10% 
isopropanol, and 2% Triton X-100) plus 1.25 pl 28% dithiothreitol (DTT), 0.62 
pl 0.5% ampholyte (pH 4.0 to 7.0 [Amersham]), and 0.01% bromophenol blue 
containing 200 pg of proteins. Three preset programs were executed with slight 
modifications so that the focusing conditions consisted of the conditioning step, 
voltage ramping, and final focusing.
The purpose of the conditioning step (500 V for 30 min) was to remove salt 
ions and charged contaminants, and this was followed by linear voltage ramping 
for 30 min at 1,000 V. In the final focusing step, the maximum voltage of the 
ramp step was maintained (up to 5,000 V • h) and the current did not exceed 50 
pA/strip. After IEF, the strips were equilibrated in 50 mM Tris buffer (pH 8.8) 
containing 6 M urea, 2% sodium dodecyl sulfate, 30% glycerol, and 1% DTT, 
followed by another 1-h equilibration step with the same buffer supplemented 
with 4.5% iodoacetamide. Sodium dodecyl sulfate-polyacrylamide gel electro­
phoresis was performed according to the Laemmli method (35) with a 12.5% 
resolving polyacrylamide gel without a stacking gel. Separation in the second 
dimension was carried out at 40 V at 4°C until the running dye reached the 
bottom.
Coomassie staining and gel drying. Proteins resolved on gels were visualized 
by using a colloidal Coomassie staining method (http://prospector.ucsf.edu) with 
slight modifications. Briefly, the gel was fixed in a solution containing 30% 
ethanol-2% phosphoric acid with double-distilled water (ddH2O) three times for 
30 min each time. All incubations were performed with gentle shaking. After a 
fixing step, the gel was washed with a solution of 2% phosphoric acid in ddH2O 
three times for 20 min each time. The wash solution was discharged, and the gels 
were fixed again with a solution containing 2% phosphoric acid (vol/vol), 18% 
ethanol (vol/vol), and 15% ammonium sulfate (wt/vol) in ddH2O for 30 min. To 
this solution, a 1.5% volume of a suspension of 2% colloidal Coomassie (G-250) 
in ddH2O was added. The duration of this step was 24 to 72 h.
Image analysis. A gel image was obtained by scanning Coomassie-stained gels 
with the Fluor-S Multiimager (Bio-Rad). The image was documented through 
the PDQUEST 2-D gel analysis software (version 6; Bio-Rad).
In-gel tryptic digestion of proteins. Coomassie-stained spots were excised from 
2-DE gels and transferred into microcentrifuge tubes. Plugs were washed with 
100 |jl1 25 mM ammonium bicarbonate for 10 min and incubated for 30 min at 
60°C in 20 pl of 5 mM DTT in 25 mM ammonium bicarbonate solution. This step 
was followed by another incubation for 15 min at room temperature in darkness 
with 20 pl 55 mM iodoacetamide in 25 mM ammonium bicarbonate. The solu­
tion was discharged, and a new wash with 25 mM ammonium bicarbonate was 
performed, followed by another wash with 100 pl acetonitrile. Then, the spots 
were subjected to a dehydration step three times with 25 pl acetonitrile for 10 
min at room temperature. When the gel spots became completely white, the 
acetonitrile was eliminated by evaporation. Spot rehydration was performed with 
small volumes (up to 20 pl) of 50 mM ammonium bicarbonate containing trypsin 
(20 pg/ml) and incubation for 45 min at 4°C. The tryptic digestion was carried out 
overnight at 37°C. After digestion, the spots were washed twice with 20 pl 
acetonitrile-0.1% trifluoroacetic acid (33:66) for 10 min, and the supernatants 
were collected. Sample concentration was performed in a Speedvac.
Peptide mass fingerprinting. A matrix solution composed of a-cyano-4-hy- 
droxy cinnamic acid (0.2 g/liter) in 50% acetonitrile and 0.25% trifluoroacetic 
acid was prepared for peptide mass fingerprinting. A 0.4-pl mixture of matrix and 
sample solutions was applied to the target well. The solution mixture was dried 
for 10 min at room temperature and subjected to a matrix-assisted laser desorp­
tion ionization-time of flight mass spectrometry operation by using an Ultraflex 
(Bruker) with the following parameters: 20-kV accelerating voltage, 75% grid 
voltage, 0.02% guide wire voltage, 70-ns delay, and a mass gate of 800 to 3,000.
Identification of proteins. Searches for and identification of peptides were 
performed with a licensed version of MASCOT software (Matrix Science) in a 
database containing the 3,436 accession number entries derived from the com­
plete B. pertussis genome sequence (downloaded from http://www.ncbi.nlm.nih 
.gov/). The MASCOT search parameters were as follows: (i) species, bacteria 
(eubacteria): (ii) allowed number of missed cleavages (only for trypsin digestion), 
one: (iii) variable posttranslational modification, methionine oxidation: (iv) fixed 
modification, carbamidomethylation: (v) peptide tolerance, ± 50 ppm; (vi) pep­
tide charge, positive: and (vii) monoisotopic peptide masses were used to search 
the database, allowing a molecular mass range for 2-DE analyses of ±15%. Only 
significant hits as defined by MASCOT probability analysis were considered.
Prediction of protein localization was carried out using a PSORT algorithm 
available at http://psort.nibb.ac.jp.
RESULTS AND DISCUSSION
Genotypic analysis. Polymorphism and variation in viru­
lence factors and strains have been observed in different coun­
tries that use whole-cell pertussis vaccines where nonvaccine 
strains are circulating (9, 19, 21, 25, 30, 36, 49, 50). In this 
study, we used PFGE and pm and ptxSl typing to add new 
insight into the characterization of B. pertussis isolates ob­
tained in Argentina in two periods: 1969 to 1989 and 1997 to 
2006.
Since it was previously reported that PFGE analysis with 
Xbal gave optimal discrimination (1, 28), we used this enzyme 
to classify the vaccine strains and local isolates into PFGE 
profile groups. Figure 1 shows the dendrogram of DNA profile 
relatedness calculated by the unweighted pair group method 
using arithmetic averages clustering of Dice coefficients. A 
total of 39 distinct PFGE profiles, named VI to V3 for vaccine 
strains, R1 for the reference strain, and Al to A35 for clinical 
isolates, were observed. These profiles were classified into six 
major groups (I to VI) based on a criterion of similarity higher 
than 0.70. The three groups corresponding to the vaccine 
strains B. pertussis 10536 (group I, which also includes the 
WHO reference strain 18323), Tohama (group II), and B. 
pertussis 134 andB. pertussis 509 (group III, which also includes 
the clinical isolate B. pertussis 8901) had low similarity with all 
Argentinean clinical isolates tested, with relatedness of 67%. 
Most Argentinean isolates fell in a small number of PFGE 
groups. Eleven isolates were segregated into PFGE group IV, 
one into PFGE group V, and 44 into PFGE group VI. PFGE 
group IV was the only one detected among the strains from 
earlier than 1982, while only a single 1982 isolate corresponded 
to PFGE group V. While 6 contemporary B. pertussis isolates 
(12%) were clustered in PFGE group IV, 44 (88%) were 
grouped in PFGE group VI. PFGE group IV seems to have 
been dominant till at least 1982, and group VI has been dom­
inant from 1998/2000 to 2006 (Fig. 1).
This lower-than-expected level of B. pertussis population di­
versity may be a consequence of sequential bottlenecks or 
fitness differences between the strains that favored only those 
variants able to evade the immunity induced by vaccination or 
with increased virulence. That is, circulating bacteria could 
have overcome the strong bottleneck of the immunity induced 
by the vaccine strain by accumulating mutations that allowed 
them to evade host responses.
Differences between circulating bacteria and vaccine strains 
were also observed when the sequences of ptxSl and pm alleles 
(38) were analyzed. Studies of ptxSl subunit polymorphism 
showed that 53 B. pertussis isolates contained the ptxSIA allele 
and only 4 had non-A ptxSl. By contrast, the vaccine strains 
used in Argentina contain ptxSIB or ptxSID alleles. For per- 
tactin, a significant correlation was observed between the 
PFGE groups and pm alleles. All 11 of the isolates from group 
IV containedpml, and all isolates from group VI had thepm2 
allele. It seems that pm2 has replaced the pml present in old 
isolates.
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FIG. 1. Genomic analysis of Argentinean B. pertussis isolates. On the left are shown chromosomal DNA profiles obtained after digestion 
with Xbal.
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In the United Kingdom and Finland, a change from pml to 
pm2 was observed in isolates from as early as 1982, in The 
Netherlands from 1990, and in Taiwan from 1997 (16, 21, 36, 
41). These same variations seem to support a possible expla­
nation that the impact of the vaccination-induced immune 
responses to these epitopes that have been recorded were 
strong enough to structure the population into discrete com­
binations of epitopes or antigenic types. By contrast, under 
weak immune selection, a greater antigenic and genetic vari­
ability of the bacterial population is expected, as occurs, for 
example, with the poorly immunogenic meningococcus sero- 
group B capsular polysaccharide, which shows high genetic 
variability (3).
Though the genotypic divergences between the vaccine 
strains and the circulating bacterial population are clear, im­
portant questions remain. Among them is whether the B. per­
tussis population genotypic variation has affected vaccine effi­
cacy and contributed to resurgence. Though it seems to be too 
early to predict this, since the shift in virulent B. pertussis 
alleles has continued over the years, it is important to begin to 
analyze the consequence of the structural genomic variation in 
pertussis protection using the accepted animal model.
Animal studies. To analyze the implications of divergence 
between vaccine strains and clinical isolates for protection, we 
used an intranasal mouse challenge model. Briefly, this model 
consists of two immunizations of mice (3- to 4-week-old 
BALB/c mice) with either current pertussis whole-cell vaccine 
or a vaccine prepared by us containing the representative B. 
pertussis 106 clinical isolate. This isolate was selected to rep­
resent the circulating bacterial population because it comes 
from the most differentiated and major PFGE group (PFGE 
group VI). The immunized mice were then intranasally chal­
lenged with sublethal doses of either a B. pertussis vaccine 
strain or the representative clinical isolate, B. pertussis 106. 
Control animals were vaccinated with PBS. Two hours later 
and on days 5 and 8 after the challenge, the lungs were col­
lected for bacterial counts. As expected, significant differences 
between immunized animals and the control group were ob­
served (P < 0.001) (Table 1). Adequate elimination rates were 
observed in mice immunized and challenged with the same 
kind of strain (immunization and challenge with a vaccine 
strain). However, a lower potential of protective immunity 
induced by whole-cell vaccination was observed in elimination 
rates of the clinical B. pertussis isolate B. pertussis 106 (pm2 
ptxSIA) from the lungs than for the vaccine strain Tohama 
(pml ptxSIB) (P < 0.001) (Table 1). Furthermore, when mice 
were immunized with a vaccine containing a clinical isolate and 
challenged with a vaccine strain or antigenically divergent clin­
ical isolates, lower clearance efficiency for the vaccine strain 
was induced (P < 0.002) as early as day 5 after challenge 
(Table 1).
These results could not be attributed to differences in colo­
nization abilities between the vaccine strain and the clinical 
isolate, since the number of colonies recovered at each time in 
infection experiments were the same for both strains (not 
shown). Overall, these results clearly demonstrate that the 
efficacies of whole-cell vaccines depend on the relatedness 
between the vaccine strains and the circulating strains. In ad­
dition, the present observations support the hypothesis of the 
role of divergence of circulating strains in pertussis resurgence.
d Bacteria recovered after challenge (log10
Immunization chXge CFU/lung ± SD) on da/:
TABLE 1. Lung clearance efficiency of diphtheria-tetanus- 
whole-cell pertussis vaccine and wPZJ/ 106 in intranasal­
challenge model experiments
strain/isolate 0 5 8
PBS Tohama 6.70 ± 0.13 6.45 ± 0.30 6.05 ± 0.28
DTwP Tohama 6.45 ± 0.73 5.20 ± 0.04 _b
wPfip 106 Tohama 6.90 ± 0.8 3.20 ± 0.19 ND
PBS 106 6.79 ± 0.13 6.51 ± 0.30 5.86 ± 0.28
DTwP 106 6.45 ± 0.02 5.41 ± 0.26 5.34 ± 0.05
WPbp106 106 6.80 ± 0.04 1.99 ± 0.74 ND
a Values shown are means of three or four animals sacrificed at each time 
point. ND, not determined.
b CFU were not detected in the lung samples.
Proteomic analysis. For further characterization of bacterial 
divergence, we compared the bacterial surfaceomes of three 
known B. pertussis strains that are widely used for vaccine 
production and that clustered in different PFGE groups: B. 
pertussis 10536 (PFGE group I), Tohama I (PFGE group II), 
and 509 (PFGE group III), and extended this analysis to the 
representative local isolate, B. pertussis 106 (PFGE group VI). 
Several protocols have been developed for the preparation and 
analysis of membrane proteins, but none of them have yet been 
used for Bordetella. The procedure employed here allowed us 
to obtain an enriched fraction of surface proteins as estab­
lished by PSORT analysis. Of the 54 proteins successfully iden­
tified, 9 were predicted to be associated with the external 
membrane, 6 had periplasmic localization, 6 had cytoplasmic/ 
membrane localization (5 harbored signal peptide), 16 had an 
unknown origin (3 had signal peptide), and 17 had a cytoplas­
mic localization (Table 2). In the last group, some of the 
proteins, such as EF-Tu, ET TS, enolase, 60-kDa chaperonin, 
and some dehydrogenases, may be associated with membranes, 
as was observed in Neisseria meningitidis (17).
Some of the proteins separated by 2-DE were present as 
multiple spots exhibiting variability in pl values (horizontal 
spot patterns) (Fig. 2). Charge variants included EF-Tu, 60- 
kDa chaperonin, outer membrane porin protein precursor, 
serum resistance protein, and serine protease. These may rep­
resent natural isoforms or an artifact caused by sample prep­
aration or 2-DE. Similarly, serum resistance protein resolved 
in multiple spots of differing masses and pls, suggesting possible 
protein processing, degradation, and/or modifications (Fig. 2).
Few proteins could be detected as differential among the 
three analyzed vaccine strains. Leu-Ile-Val protein precursor 
(spot 17; BP1285), DNA direct RNA a subunit polymerase 
(spot 18; BP3642), and a two-component sensor protein (spot 
31; BP2483) could be detected in Tohama and /< pertussis 509; 
however, they were not detected in strain 10536. Putative pen­
icillin binding protein precursor (spot 50; BP0102) and hypo­
thetical protein BP3128 (spot 39; BP3128) were detected in B. 
pertussis 509 and 10536 but were not evident in Tohama, and 
putative binding protein-dependent transport protein (spot 10; 
BP3322) was not observed in B. pertussis 509, whereas putative 
molibdopterin oxidoreductase (spot 22; BB0468) was clearly 
detected in B. pertussis 10536. Furthermore, putative ABC 
transport ATP binding protein (spot 8; BP3757) and putative
Downloaded from http://cvi.asm
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TABLE 2. Surface proteome of B. pertussis vaccine strains Tohama, 10536, and 509 and Argentinean clinical isolate 106
Order Protein name/function Gene locus0 Mass (kDa) Pl Protein localization6
Presence of gene in strain6:
Tohama 509 10536 106
1 Competence lipoprotein precursor BP1146 29.8 5.0 Unknown Yes Yes Yes Yes
2 Conserved hypothetical protein BP3441 19.8 5.1 Cytoplasmic/memb rane' Yes Yes Yes Yes
3 Adhesin BP2667 263.6 9.7 Outer membrane Yes Yes Yes Yes
4 Putative lipoprotein BP1296 30.6 7.4 Unknown Yes Yes Yes Yes
5 Succinate dehydrogenase catalytic 
subunit
BP2360 27.2 6.2 Cytoplasmic Yes Yes Yes Yes
6 Outer membrane protein OMPQ BP3405 39.1 5.7 Outer membrane6 Yes Yes Yes Yes
7 Outer membrane porin protein 
precursor
BP0840 41 5.4 Outer membrane Yes Yes Yes Yes
8 Putative ABC transport ATP 
binding protein
BP3757 29.6 5.1 Unknown Yes6 Yes Yes Yes
9 Putative periplasmic solute binding 
protein
BP1487 40 7.8 Unknown6 Yes Yes Yes Yes
10 Putative binding protein-dependent 
transport protein
BP3322 40.9 6.94 Periplasmic Yes No Yes Yes
11 Putative membrane protein BP1440 33.4 5.3 Unknown" Yes’5 Yes Yes Yes’5
12 Antioxidant protein BP0965 23.7 5.7 Cytoplasmic Yes Yes Yes Yes
13 Serin protease BP2434 52.1 8.8 Periplasmic Yes Yes Yes Yes
14 Chaperonin, 60 kDa BP3495 57.4 4.9 Cytoplasmic^ Yes Yes Yes Yes
15 Serum resistance protein BP3494 103.3 7.1 Outer membrane Yes Yes Yes Yes
16 EF Tu BP0007 42.9 5.1 Cytoplasmic^ Yes Yes Yes Yes
17 Leu-Ile-Val protein precursor BP1285 39.6 6.8 Periplasmic Yes Yes No No
18 DNA direct RNA a subunit 
polymerase
BP3642 36.1 5.7 Cytoplasmic Yes Yes No Yes
19 Pertactin BP1054 93.4 10 Outer membrane Yes Yes Yes Yes
20 Putative quino protein BP2196 40 8.7 Unknown Yes Yes6 Yes Yes
21 Putative extracellular solute 
binding protein
BP3862 57.3 9.7 Cytoplasmic/memb rane6 Yes Yes Yes No
22 Putative molibdopterin 
oxidoreductase
BB0468 121.6 7.3 Periplasmic No No Yes No
23 Outer membrane protein A 
precursor
BP0943 20.9 9.2 Outer membrane6 Yes Yes Yes Yes
24 Superoxide dismutase BP2761 21.2 6.5 Unknown Yes Yes Yes Yes
25 Putative exported protein BP2513 34.9 10.2 Outer membrane Yes Yes Yes Yes
26 Ubiquinol cytochrome c reductase 
iron sulfur subunit
BP0277 22.8 5.2 Cytoplasmic/memb rane6 Yes Yes Yes Yes
27 Putative exported protein BP2755 189 6.2 Cytoplasmic/memb rane6 Yes Yes Yes No
28 3-Oxoacyl-(acyl carrier protein) 
synthase
BP2439 43.6 5.7 Cytoplasmatic No No No Yes
29 Putative bacterial secretion system 
protein
BP3794 29.4 6.8 Unknown6 Yes Yes Yes Yes
30 Enolase BP2386 45.9 4.5 Cytoplasmic^ Yes Yes Yes Yes
31 Two-component sensor protein BP2483 97.4 8.7 Cytoplasmic/memb rane Yes Yes No No
32 Serum resistence protein BP3494 103.3 7.1 Outer membrane Yes Yes Yes Yes
33 Succinate dehydrogenase flavo 
subunit
BP2361 64.8 6.5 Cytoplasmic Yes Yes Yes Yes
34 Putative ABC transport solute 
binding protein
BP2747 40.6 6.5 Cytoplasmic/memb rane6 Yes Yes Yes Yes
35 ATP synthase subunit B BP3288 50.5 4.7 Cytoplasmic Yes Yes Yes Yes
36 EF Ts BP1420 30.9 5.1 Cytoplasmic^ Yes Yes Yes Yes
37 Ribose phosphate
pyrophosphokinase
BP3125 34.1 5.1 Unknown No No No Yes
38 Dihydrolipoamide dehydrogenase BP0995 62.3 5.8 Cytoplasmic No No No Yes
39 Hypothetical protein BP3128 68.5 6.1 Unknown No Yes Yes Yes
40 Hypothetical protein BP3515 35.9 6.6 Unknown Yes Yes Yes Yes
41 Polysaccharide biosynthesis protein BP3150 46.7 5.6 Cytoplasmic No No No Yes
42 Capsular polysaccharide 
biosynthesis protein
BP1630 37.3 5.7 Unknown No No No Yes
43 Putative L-lactate dehydrogenase BP0379 37.2 5.8 Unknown No No No Yes
44 Hypothetical protein BP2964 48.5 6.2 Cytoplasmic Yes Yes No Yes’5
45 Hypothetical protein BP1203 42.7 6 Unknown Yes Yes Yes Yes
46 Putative sigma factor regulatory? 
protein
BP2435 39.2 9.6 Periplasmic No No No Yes
47 Enoyl-acyl carrier protein BP3215 27.6 5.8 Unknown Yes Yes Yes Yes
48 Lipoprotein BP2750 23.1 7.7 Unknown Yes Yes Yes Yes
49 Alkyl hydroperoxide reductase BP3552 20.1 4.9 Cytoplasmic Yes Yes Yes Yes
50 Putative penicillin binding protein 
precursor
BP0102 44.8 7.9 Periplasmic No Yes Yes Yes
51 Dihydrolipoamide dehydogenase BP1126 50.1 6.7 Cytoplasmic No No No Yes
52 Trigger factor BP1774 47.5 4.9 Cytoplasmic Yes Yes Yes Yes
53 Putative type III secretion protein BP2235 63.3 5.9 Outer membrane No No No Yes
54 Hypothetical protein BP3559 37.9 4.7 Cytoplasmic Yes Yes Yes Yes
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a Gene loci are named according to NCBI (http://www.ncbi.nlm.nih.gov/). 
b Protein localization is as predicted by PSORT (http://psort.nibb.ac.jp).
6 Signal peptide present.
d Membrane associated in other bacteria.
6 Greater quantity.
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A
____________________kDa
97
66
45
30
20
pH 4 7
c kDa
-97
-66
-45
-30
-20
pH 4 7
1- competence lipoprotein precursor bp 1146
2- conserved hypothetical protein bp3441
3- adhesin bp2687
4- putative lipoprotein bp 1296
5- succinate deshydrogenase catalytic subunit bp2360
6- outer membrane protein OMPQ i?p3405
7- outer membrane porin protein precursor bp0840
6- putative ARC transporter, ATP binding protein t>p3757
9- putative periplasm io solute binding protein bp 14 87
10- putative binding protein dependent transport protein dp3322
11- hypothetical protein bpl440
12- antioxidant protein bp0965
13- serin protease bp2434
14- chaperonin 60 kDa bp3495
15- serum resistance protein bp3494
16- elongation factor Tu bp0007
17 - leu-lle-Val protein precursor ftp 1285
18- DNA direct RNA a subunit polymerase
19- pertactin
20- putative qulno protein bp2196
21- putative extracellular solute binding protein bp3862
22- putative molibdopterin oxidoreductase bb0468
23- outer membrane protein A precursor ¿p0$43
24- superoxide dismutase bp276i
25- putative exported protein bp2513
26- ubiquinol cytochromo C reductase iron 
sulfur subunit bp0277
27- putative exported protein bp2755
28- 3-oxoacyl-(acyl carrier protein} synthase Pp2439
29- putative bacterial secretion system protein bp3794
30- enolase bp2386
31- Two component sensor protein bp2483
32- serum resitance protein bp3494
33- succinate deshydrogenase flavo subunit bp236f
34- putative ABC transport solute binding protein bp2747
35- ATP synthase subunit B bp3288
36- elongation factor TS bp1420
37- ribose phosphate pyrophosphokinase bp3125
38- dihydrolipoamide deshydrogenase PpO995
39- Hypothetical protein
40- hypothetical prolein bp3515
41- polysaccharide biosynthesis protein bp3150
42- capsular polysaccharide biosynthesis protein bp 1630
43- putative L lactacto deshydrogenase bp<?379
44- hypothetical protein ¿p2964
45- hypothetical protein tp-i203
46- putative sigma factor regulaton/ protein bp2435
47- enoyl-acyl carrier protein £>p3275
48- lipoprotein tjp2750
49- alkyl hydroperoxide reductase bp3552
50- putative penicilin binding protein precursor bp0102
51- dihydrolipoamide dehydrogenase bjDl126
52- trigger factor bp1774
53- putative type 111 secretion protein bp2235
54- hypothetical protein t?p3559
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FIG. 2. Separation and identification of membrane-related proteins in B. pertussis enriched membrane samples using two dimensional polyacrylamide gel 
electrophoresis, followed by matrix-assisted laser desorption ionization-time of flight mass spectrometry. (A) B. pertussis 509. (B) B. pertussis 10536. (C) B. 
pertussis Tohama. (D) B. pertussis 106. All samples were resolved by IEF (pH 4 to 7). Protein spots were visualized by colloidal Coomassie staining.
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membrane protein (spot 11; BP1440) were detected in strain 
Tohama in smaller quantities than in strains 509 and 10536, 
and putative quinoprotein (spot 20; BP2196) was detected at a 
high level in B. pertussis 509 but in small quantities in B. 
pertussis 10536 and Tohama.
While a number of protein spots were common among the 
vaccine strains tested and the clinical isolate B. pertussis 106, 
there were multiple spots unique to B. pertussis 106, i.e., ribose 
phosphate pyrophosphokinase (spot 37; BP3125), dihydrolipo­
amide dehydrogenase (spot 38; BP0995), polysaccharide bio­
synthesis protein (spot 41; BP3150), capsular polysaccharide 
biosynthesis protein (spot 42; BP1630), putative L-lactacte de­
hydrogenase (spot 43; BP0379), a hypothetical protein (spot 
44; BP2964, which is present in greater quantity than was 
observed in Tohama and 10536), putative sigma factor regula­
tory protein (spot 46; BP2435), dihydrolipoamide dehydroge­
nase (spot 51; BP1126), and putative type III secretion protein 
(spot 53; BP2235). The presence of the last protein is an 
interesting result, since it was previously reported that the type 
III secretion system is expressed only in Bordetella bronchisep- 
tica. This result is in agreement with the work presented by 
K. Mills at the Eighth International Symposium: Saga of Ge­
nus Bordetella, 1906 to 2006, at the Institut Pasteur, Paris, 
France. He described an effector of the type III secretion 
system that was found solely in clinical isolates and not in 
laboratory-adapted B. pertussis strains.
Though most of the proteins identified in B. pertussis 106 are 
involved in carbohydrate metabolism, some of them were re­
cently described in other gram-negative bacteria as having 
roles in pathogenicity (12) and immunogenicity (33).
One of these enzymes is the dihydrolipoamide dehydroge­
nase (Lpd), which is an essential functional subunit of the 
multienzyme pyruvate dehydrogenase complex, with a pre­
dicted molecular mass of 50.37 kDa. The pyruvate deshydro- 
genase complex is comprised of multiple copies of the ternary 
complex of Lpd, dihydrolipoamide transacetylase, and pyru­
vate dehydrogenase enzymes and is involved in the oxidation of 
pyruvate. The dihydrolipoamide dehydrogenase enzyme allows 
the continued function of the pathway by maintaining the cor­
rect redox state of the enzymes involved in the bioconversion. 
For Mycobacterium, it was reported that Lpd has an important 
role in host colonization and pathogenesis, and in H. influenzae 
type B, a transposon insertion in IpdA, a dihydrolipoamide 
dehydrogenase gene homolog, converts the virulent bacteria 
into attenuated bacteria. When the H. influenzae LpdA mutant 
was used to challenge 5-day-old infant rats intraperitoneally, it 
was unrecoverable compared to the wild-type recovery rate 
(29). These evidences point out that the Lpd identified in B. 
pertussis 106 may have a role in pathogenicity that needs to be 
investigated.
In B. pertussis 106, two other differing spots were detected: 
polysaccharide biosynthesis protein (spot 41; BP3150) and cap­
sular polysaccharide biosynthesis protein (spot 42; BP1630). 
Since capsules are often key contributors to the abilities of 
pathogens to withstand host defense mechanisms (42), the 
expression of these proteins in B. pertussis 106 may be a con­
sequence of its need to evade the host immune response in­
duced by vaccination. A locus that is likely to encode a type II 
polysaccharide capsule (20) comprising three regions that are 
involved in export/modification, biosynthesis, and transport 
was previously reported to be present in the Bordetella genome 
sequence (45). In B. pertussis strain Tohama, it was reported 
that the central part of the locus is intact but that the 3' region 
of one gene has undergone an inversion event and, at the 5' 
end of the locus, an insertion element-mediated rearrange­
ment has deleted part of region 1 (which contains genes 
that are involved in export/modification) and moved two of 
the export genes to a different part of the chromosome. It 
will be interesting to analyze the structure of this locus in B. 
pertussis 106.
This study not only shows that the previously observed 
genomic divergences between the Argentinean circulating B. 
pertussis population and vaccine strains is now registered (by 
the Public Health Ministry), but more importantly, that these 
genomic differences have implications for pertussis protection 
and could also be extended to the protein expression patterns.
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